Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ATM | Q13315 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | ROS1 | P08922 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1165494 | 0.85 | ALDH1A1 (0.45) | KDM4EALDH1A1GAAMAPTNPC1 | |
| SCHEMBL2472619 | 0.80 | MAPT (0.57) | KDM4EHTTALDH1A1GAAMAPT | |
| SCHEMBL29690270 | 0.80 | ALDH1A1 (0.44) | KDM4EALDH1A1MAPTTSHRCA1 | |
| SCHEMBL6032230 | 0.80 | TSHR (0.40) | HTTALDH1A1GAAMAPTNPC1 | |
| SCHEMBL3524389 | 0.80 | ALDH1A1 (0.44) | KDM4EALDH1A1MAPTTSHRCA1 | |
| SCHEMBL730039 | 0.80 | KMT2A (0.42) | KDM4EHTTALDH1A1GAAMAPT | |
| SCHEMBL1814052 | 0.77 | KMT2A (0.41) | KDM4EALDH1A1MAPTRAB9AHSD17B10 | |
| SCHEMBL31217566 | 0.77 | PPIB (0.54) | KDM4EHTTALDH1A1GAAMAPT | |
| SCHEMBL3537702 | 0.77 | TSHR (0.38) | KDM4EATMHTTALDH1A1GAA | |
| SCHEMBL31217571 | 0.77 | KDM4E (0.44) | KDM4EATMHTTRAD52ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2355810-B1 | COMPOUND FOR THE TREATMENT OF PSORIASIS | NOGRA PHARMA LTD (IE) | 2017-07-12 | — | — | EP | disclosed |
| US-20120316230-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| US-8138357-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-03-20 | — | — | US | disclosed |
| WO-2010063472-A1 | METHODS FOR PREVENTING OR REDUCING COLON CARCINOGENESIS | GIULIANI INTERNATIONAL LIMITED (IE) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010063470-A2 | METHODS FOR PREVENTING OR REDUCING CARCINOGENESIS OR OXIDATIVE STRESS | GIULIANI INTERNATIONAL LIMITED (IE) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316230-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | KDM4E 4435/4885ATM 1880/4885HTT 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.